Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

International Prospective Study on Adherence to Treatment in Patients With Active Systemic Lupus Erythematosus (TPASLE)

This study is currently recruiting participants. (see Contacts and Locations)
Verified November 2011 by Assistance Publique - Hôpitaux de Paris
Sponsor:
Information provided by (Responsible Party):
Assistance Publique - Hôpitaux de Paris
ClinicalTrials.gov Identifier:
NCT01509989
First received: December 1, 2011
Last updated: March 4, 2013
Last verified: November 2011

December 1, 2011
March 4, 2013
January 2013
June 2013   (final data collection date for primary outcome measure)
Adherence to the treatment in the whole group. [ Time Frame: participants will be followed for the duration of hospital stay, an expected average of 1 ] [ Designated as safety issue: No ]
The end points are adherence of the treatment in the whole group(defined by very low blood HCQ concentration)
Adherence to the treatment in the whole group. [ Time Frame: participants will be followed for the duration of hospital stay, an expected average of 1 ] [ Designated as safety issue: No ]
The end points are adherence of the treatment in the whole group
Complete list of historical versions of study NCT01509989 on ClinicalTrials.gov Archive Site
Secondary outcome [ Time Frame: up to 3 weeks ] [ Designated as safety issue: No ]

Adherence according to central nervous system, to pregnancy, to the severity of SLE, to the center and the country.

Adherence in the group of patients fulfilling the eligibility criteria of studies on monoclonal antibodies, The relationship between patients questionnaires, physician evaluation of adherence and blood HCQ dosage Interest of MASRI and Morisky questionnaires in the prediction of non-adherence Factors associated with poor adherence

The socio-economic aspect of blood HCQ concentration measurement Pharmacokinetics studies on HCQ, with comparison to another cohort

Secondary outcome measures of Adherence to the treatment [ Time Frame: up to 3 weeks ] [ Designated as safety issue: No ]

Adherence according to central nervous system, involment to pregnancy, severity of SLE, the center and the country.

Adherence in the group of patients fulfilling the eligibility criteria of studies on monoclonal antibodies, The relationship between patients questionnaires, physician evaluation of adherence and blood HCQ dosage Interest of MASRI and Morisky questionnaires in the prediction of non-adherence Factors associated with poor adherence

The socio-economic aspect of blood HCQ concentration measurement Pharmacokinetics studies on HCQ, with comparison to another cohort

Not Provided
Not Provided
 
International Prospective Study on Adherence to Treatment in Patients With Active Systemic Lupus Erythematosus
International Prospective Study on Adherence to Treatment in Patients With Active Systemic Lupus Erythematosus

The treatment of systemic lupus erythematosus (SLE) may change in the future due to the availability of new biological treatments, especially monoclonal antibodies in patients with active disease. However, one of the main causes of treatment failure in SLE is the lack of treatment adherence since "drugs don't work in patients who don't take them." Hydroxychloroquine (HCQ-Plaquenil) has a long terminal elimination half- life, and investigators have demonstrated that patients who do not take HCQ for a long time have undetectable or very-low blood HCQ concentrations (< 200 ng/ml). The rate of severe non-adherence was 7% in a cohort of 203 patients and was even higher in patients with active disease: 8 out of 35 (23%) in patients with a SLEDAI ≥6 and 6 out of 20 (30%) in patients with a SLEDAI ≥12.

Investigators will evaluate the importance of non-adherence to the treatment in a large population of SLE patients with active disease. This will be done with blood HCQ monitoring in a translational multicentric prospective study.

This international multicentric prospective study is an observational study that will include consecutive SLE patients treated with HCQ and with SLE flare (defined by the SELENA-SLEDAI flare composite). The study will only require the sampling of 1 vial of whole blood for the dosage of HCQ (that would be centralized and performed in PITIE-SALPETRIERE Hospital at the completion of the study). The patients and the physicians will also have adherence self-questionnaires to complete, and the physicians will complete a patient data sheet.

The end points are adherence of the treatment in the whole group, and subgroups, adherence according to the severity of SLE, and the relationship between patient's questionnaires, physician evaluation of adherence and blood HCQ dosage.

If investigators confirm their previous data, this study might demonstrate that a significant proportion of patient candidates for treatment escalation are in fact nonadherent to the treatment. It might further demonstrate the interest of HCQ concentrations monitoring, both in "real life" and in therapeutic study in SLE as it may avoid unnecessary, expensive or even hazardous regimen escalation.

Observational
Time Perspective: Prospective
Not Provided
Retention:   Samples With DNA
Description:

blood

Probability Sample

Active Systemic Lupus Erythematosus (see eligibility criteria)

Systemic Lupus Erythematosus
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
300
January 2015
June 2013   (final data collection date for primary outcome measure)

Inclusion criteria :

  • History of meeting 4 American College of Rheumatology (ACR) criteria for systemic lupus erythematosus including a positive test for antinuclear antibodies,
  • SLE flare defined by the SELENA-SLEDAI flare composite
  • Treatment with HCQ for at least 2 months with a daily dosage > or equal to 200 mg/day.

Exclusion criteria :

  • Patients who are not able to take their medications (notably patients with repeated vomiting and patients who are not allowed to take oral medications)
Both
6 Years to 80 Years
No
Contact: Nathalie Costedoat-Chalumeau, MD, PhD +33 (0) 1 42 17 80 09 nathalie.costedoat@psl.aphp.fr
France
 
NCT01509989
Record2012
Yes
Assistance Publique - Hôpitaux de Paris
Assistance Publique - Hôpitaux de Paris
Not Provided
Principal Investigator: Nathalie Costedoat-Chalumeau, MD Service de Médecine Interne, Hopital Pitié-Salpêtrière, 47-83 Boulevard de l'hôpital, 75013 Paris, France. Email : nathalie.costedoat@gmail.com
Principal Investigator: Michelle Petri, MD Dept of Rheumatology, 1830 Building, Suite 7500. Email: mpetri@jhmi.edu
Principal Investigator: Jill Buyon, MD 560 First avenue, TCH-407, New York-NY 10016. Email: jill.buyon@nyumc.org
Principal Investigator: Barri Fessler, MD Division of Clinical Immunology and Rheumatology, 510 20th Street South, Faculty Office Tower 844, University of Alabama at Birmingham, Birmingham, AL 35294. Email: bjf@uab.edu
Principal Investigator: Graciela Alarçon, MD Department of Medicine, Division of Clinical Immunology and Rheumatology, The University of Alabama at Birmingham, 830 Faculty Office Tower, 510 20th Street South, Birmingham, AL 35294-3408. Email: graciela.alarcon@ccc.uab.edu
Principal Investigator: Ann Clarke, MD Lupus Clinic, Montreal General Hospital, Room A6163, 1650 Cedar Ave, Montreal, Quebec, Canada, H3G 1A4. Email: ann.clarke@mcgill.ca
Principal Investigator: Murray Urowitz, MD Toronto Western Hospital, East Wing, 1st Floor Rm 1-409, 399 Bathurst St., Toronto, Ontario, Canada M5T 2S8. Email: m.urowitz@utoronto.ca
Principal Investigator: Anne Mackinnon, MD Toronto Western Hospital, East Wing , 1st Floor Rm 1-409, 399 Bathurst St., Toronto, Ontario, Canada M5T 2S8. Email: amackinn@uhnresearch.ca
Principal Investigator: Roger Levy, MD Department of Rheumatology, Faculdade de Ciências Médicas, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil. Email: roger.a.levy@gmail.com
Principal Investigator: Adriana Danowski, MD Lupus clinic, Department of Rheumatology, Hospital Federal dos, Servidores do Estado, Rua Sacadura Cabral 178, Rio de Janeiro, Brasil, 20221-903. E-mail: reumatopesquisa.ad@gmail.com
Principal Investigator: Frederic Houssiau, MD Rheumatology Unit, Internal Medicine Department, Cliniques universitaires Saint-Luc, Université catholique de Louvain,Bruxelles, Belgium. Email: Frederic.Houssiau@uclouvain.be
Principal Investigator: Guillermo Ruiz-Irastorza, MD Autoimmune Disease Research Unit, Internal Medicine Department,Hospital de Cruces, University of the Basque Country, Barakaldo, Spain. Email: r.irastorza@euskaltel.net
Principal Investigator: Ricard Cervera, MD Department of Autoimmune Diseases, Hospital Clínic, rcervera@clinic.ub.es Barcelona, Catalonia, Spain. Email: rcervera@clinic.ub.es
Principal Investigator: David Isenberg, MD Department Inflammation, UCL Division of Medicine, Room 331 The Windeyer Building, 46 Cleveland Street, London, England. Email: d.isenberg@ucl.ac.uk
Principal Investigator: Liz Lightstone, MD Department of Medicine, Imperial College London, South Kensington Campus, London SW7 2AZ, England. Email: l.lightstone@imperial.ac.uk
Principal Investigator: Munther Khamashta, MD Lupus Research Unit, The Rayne Institute, St Thomas' Hospital, London SE1 7EH, England. Email: munther.khamashta@kcl.ac.uk
Principal Investigator: Yehuda Shoenfeld, MD Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer 52621, Israel. Email: shoenfel@post.tau.ac.il
Principal Investigator: Ronald F. van Vollenhoven, MD Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska University Hospital, D10:0, Department of Rheumatology, 17176 Stockholm, Sweden. Email: Ronald.van.Vollenhoven@ki.se
Principal Investigator: Eric Hachulla, MD Service de Médecine Interne, Hôpital Claude Huriez, 1, place Verdun, 59000 Lille. Email: ehachulla2@yahoo.fr
Principal Investigator: Jean-François Viallard, MD Service de Médecine Interne, Hôpital Haut Lévêque, Centre François Magendie, 1, avenue Magellan, 33604 Pessac Cedex. Email: jean-francois.viallard@chu-bordeaux.fr
Principal Investigator: Loïc Guillevin, MD Service de Médecine Interne, Hôpital Cochin, 27, rue du Faubourg Saint-Jacques, 75679 PARIS Cedex 14. Email: loic.guillevin@wanadoo.fr
Principal Investigator: Luc Mouthon, MD Service de Médecine Interne, Hôpital Cochin, 27, rue du Faubourg Saint-Jacques, 75679 PARIS Cedex 14. Email: luc.mouthon@cch.aphp.fr
Principal Investigator: Veronique Leguern, MD Service de Médecine Interne, Hôpital Cochin, 27, rue du Faubourg Saint-Jacques, 75679 PARIS Cedex 14.
Principal Investigator: Jean-Charles Piette, MD Service de Médecine Interne, Hopital Pitié-Salpêtrière, 47-83 Boulevard de l'hôpital, 75013 Paris, France. Email: jcpiette@free.fr
Assistance Publique - Hôpitaux de Paris
November 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP